Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

INTRODUCTION: The rVSVDG-ZEBOV-GP (Ervebo®) vaccine is both immunogenic and protective against Ebola. However, the vaccine can cause a broad range of transient adverse reactions, from headache to arthritis. Identifying baseline reactogenicity signatures can advance personalized vaccinology and increase our understanding of the molecular factors associated with such adverse events. METHODS: In this study, we developed a machine learning approach to integrate prevaccination gene expression data with adverse events that occurred within 14 days post-vaccination. RESULTS AND DISCUSSION: We analyzed the expression of 144 genes across 343 blood samples collected from participants of 4 phase I clinical trial cohorts: Switzerland, USA, Gabon, and Kenya. Our machine learning approach revealed 22 key genes associated with adverse events such as local reactions, fatigue, headache, myalgia, fever, chills, arthralgia, nausea, and arthritis, providing insights into potential biological mechanisms linked to vaccine reactogenicity.

Original publication

DOI

10.3389/fimmu.2023.1259197

Type

Journal article

Journal

Front Immunol

Publication Date

2023

Volume

14

Keywords

Ebola, adverse events, baseline gene signatures, data integration, machine learning, personalized vaccinology, rVSVDG-ZEBOV-GP vaccine, vaccine safety, Humans, Antibodies, Viral, Arthritis, Ebola Vaccines, Ebolavirus, Headache, Hemorrhagic Fever, Ebola, Vaccination, Clinical Trials, Phase I as Topic